What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

Investigate the efficacy of brentuximab vedotin plus lenalidomide and rituximab in DLBCL patients with low CD30 expression.

December 8, 2025BloodOpen Access

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 1% expression

View Full Paper

Ask AI

Bookmark

Authors

NBNancy L. BartlettBoston University JKJeong‐Ah KimYonsei University IFIsabelle FleuryHôpital Maisonneuve-Rosemont

Discussion

Member takes

Implication

Phase 3 trial demonstrated improved progression-free survival with brentuximab vedotin and rituximab in DLBCL patients regardless of CD30 levels, suggesting effective treatment options.

Key Points

Investigate the efficacy of brentuximab vedotin plus lenalidomide and rituximab in DLBCL patients with low CD30 expression.
Randomized phase 3 trial (ECHELON-3) comparing brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab.
Patients categorized based on CD30 expression assessed by immunohistochemistry (IHC).
Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR).
Patients with CD30 <1% showed numerically greater OS and PFS benefits with brentuximab vedotin compared to placebo.
In CD30 <1% with trace staining, median OS was 15.6 months for treatment vs. 5.2 months for placebo.
ORR was 60% with brentuximab vedotin vs 34.9% with placebo, highlighting significant efficacy.

Cite This Study

Bartlett et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd76 https://doi.org/10.1182/blood-2025-1905

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial demonstrated improved progression-free survival with brentuximab vedotin and rituximab in DLBCL patients regardless of CD30 levels, suggesting effective treatment options.

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 1% expression

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 1% expression

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider